Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | RBP4 | P02753 | 4/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 2/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3210401 | 0.91 | KMT2A (0.57) | KMT2AMEN1RBP4L3MBTL1ALDH1A1 | |
| SCHEMBL8260988 | 0.83 | KMT2A (0.74) | KMT2AMEN1L3MBTL1ALDH1A1POLB | |
| SCHEMBL3225849 | 0.83 | RBP4 (0.52) | KMT2AMEN1RBP4HTR2CCNR1 | |
| SCHEMBL3205508 | 0.83 | KMT2A (0.54) | KMT2AMEN1RBP4L3MBTL1ALDH1A1 | |
| SCHEMBL3221289 | 0.82 | HSD11B1 (0.64) | KMT2AMEN1RBP4POLB | |
| SCHEMBL14686256 | 0.82 | KMT2A (0.68) | KMT2AMEN1L3MBTL1ALDH1A1POLB | |
| SCHEMBL3209386 | 0.82 | HSD11B1 (0.55) | KMT2AMEN1RBP4ALDH1A1POLB | |
| SCHEMBL3215762 | 0.82 | GPR183 (0.53) | KMT2AMEN1RBP4ALDH1A1HTR2C | |
| SCHEMBL31684031 | 0.81 | KMT2A (0.87) | KMT2AMEN1L3MBTL1ALDH1A1CHRM4 | |
| SCHEMBL3201836 | 0.80 | LMNA (0.60) | KMT2AMEN1RBP4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029648-A1 | 11-Beta HSD1 Inhibitors | XIANG JASON SHAOYUN | 2010-02-04 | — | — | US | disclosed |
| US-7632838-B2 | 11-beta HSD1 inhibitors | WYETH (US) | 2009-12-15 | — | — | US | disclosed |
| US-20070219198-A1 | 11-Beta HSD 1 inhibitors | WYETH (US) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029648-A1 | 11-Beta HSD1 Inhibitors | HSD11B1, HSD3B1, HSD11B2 | KMT2A 1609/4885MEN1 1354/4885RBP4 2175/4885 |
| US-20070219198-A1 | 11-Beta HSD 1 inhibitors | HSD11B1, HSD11B2, HSD3B1 | KMT2A 1591/4885MEN1 1687/4885RBP4 2329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.